Vnitr Lek 2021, 67(Suppl.C):3-8 | DOI: 10.36290/vnl.2021.100

Pro a předem prohraný souboj proti PCSK9 inhibitorům

MUDr. Zuzana Zafarová

Sympozium společnosti Sanofi na XXIX. výročním sjezdu České kardiologické společnosti, které proběhlo 21. 5. 2021, bylo věnováno praktickému využití inhibitorů PCSK9 (PCSK9i) v léčbě dyslipidemie u pacientů s vysokým a velmi vysokým kardiovaskulárním (KV) rizikem. Šest předních českých kardiologů rozebralo 3 kazuistiky, na kterých prezentovali přínos alirocumabu u pacienta s familiární hypercholesterolemií (FH), pacienta po akutním koronárním syndromu (AKS) a pacientky s ischemickou chorobou srdeční (ICHS) bez možnosti revaskularizace, u nichž využili alirocumab k potřebnému výraznému snížení LDL cholesterolu k cílovým hladinám. Vysvětlili, že u pacientů s intenzivní statinovou léčbou, kteří mají stále více než dvojnásobek cílové hladiny LDL cholesterolu, je přidání PCSK9i jedinou cestou, jak požadovaného poklesu dosáhnout, protože přidání ezetimibu tak výrazný efekt nemá. Vzhledem k tomu, že úhradová kritéria tento postup umožňují, pokud je medicínsky odůvodněný, lze využít PCSK9i k příznivému ovlivnění prognózy nemocných doloženému významným snížením rizika KV příhod a celkové mortality.

Published: October 25, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zafarová Z. Pro a předem prohraný souboj proti PCSK9 inhibitorům. Vnitr Lek. 2021;67(Suppl. C - Novinky v k):3-8. doi: 10.36290/vnl.2021.100.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Freiberger T, Vaclová M, Tichý L, et al. Familiární hypercholesterolemie v České republice v roce 2016. Vnitr Lek 2016; 62(11): 924-928. Go to PubMed...
    2. Vrablík M, Vaclová M, Tichý L, et al. Familial hypercholesterolemia in the Czech Republic: more than 17 years of systematic screening within the MedPed project. Physiol Res 2017; 66(Suppl 1): S1-S9. Go to original source... Go to PubMed...
    3. Li S, Zhang HW, Guo YL, et al. Familial hypercholesterolemia in very young myocardial infarction. Sci Rep 2018; 8(1): 8861. Go to original source... Go to PubMed...
    4. Khera AV, Won HH, Peloso GM, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. J Am Coll Cardiol 2016; 67(22): 2578-2589. Go to original source... Go to PubMed...
    5. Mach F, Baigent C, Catapano AL, et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111-188. Go to original source... Go to PubMed...
    6. Vrablik M, Raslová K, Vohnout B, et al. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry. Atherosclerosis. 2018; 277: 355-361. Go to original source... Go to PubMed...
    7. Raal FJ, Stein EA, Dufour R, et al. RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 385(9965): 331-340. Go to original source... Go to PubMed...
    8. Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015; 36(43): 2996-3003. Go to original source... Go to PubMed...
    9. Steg PG, Szarek M, Bhatt DL, et al. Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation 2019; 140(2): 103-112. Go to original source... Go to PubMed...
    10. Sanders DW, Jumper CC, Ackerman PJ, et al. SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. Elife. 2021; 10: e65962. Go to original source... Go to PubMed...
    11. Zhang XJ, Qin JJ, Cheng X, et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab 2020; 32(2): 176-187.e4. Go to original source... Go to PubMed...
    12. Ošťádal P, Táborský M, Lihart A, et al. Stručný souhrn doporučení pro dlouhodobou péči o nemocné po infarktu myokardu. Cor et Vasa 2019; 61(5): 471-480. Go to original source...
    13. Cannon CP, Khan I, Klimchak AC, et al. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2017; 2(9): 959-966. Go to original source... Go to PubMed...
    14. Češka R, Táborský M, Vrablík M. Společné stanovisko odborných společností k předepisování inhibitorů PCSK9. AtheroRev. 2018; 3(3): 201-207.
    15. Cannon CP, Cariou B, Blom D, et al. ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015; 36(19): 1186-1194. Go to original source... Go to PubMed...
    16. Furie KL, Kasner SE, Adams RJ, et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42(1): 227-276. Go to original source... Go to PubMed...
    17. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016; 23(6): 636-648. Go to original source... Go to PubMed...
    18. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005; 19(6): 403-414. Go to original source... Go to PubMed...
    19. Banegas JR, López-García E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011; 32(17): 2143-2152. Go to original source... Go to PubMed...
    20. Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol. 2014; 176(1): 55-61. Go to original source... Go to PubMed...
    21. Koren MJ, Roth EM, McKenney JM, et al. Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis. Postgrad Med 2015; 127(2): 125-132. Go to original source... Go to PubMed...
    22. Robinson JG, Farnier M, Krempf M, et al. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372(16): 1489-1499. Go to original source... Go to PubMed...
    23. Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372(25): 2387-2397. Go to original source... Go to PubMed...
    24. Kato ET, Cannon CP, Blazing MA, et al. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc. 2017; 6(11): e006901. Go to original source... Go to PubMed...
    25. Giugliano RP, Cannon CP, Blazing MA, et al. IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018; 137(15): 1571-1582. Go to original source... Go to PubMed...
    26. Schwartz GG, Steg PG, Szarek M, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018; 379(22): 2097-2107. Go to original source... Go to PubMed...
    27. Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol 2017; 69(8): 911-921. Go to original source... Go to PubMed...
    28. Landmesser U, Pirillo A, Farnier M, et al. Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. Atheroscler Suppl. 2020; 42: e49-e58. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.